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Abstract
Genomic testing in patients with early-stage breast cancer is associated with decreased use of chemotherapy
and lower costs in younger patients, and slightly increased use of chemotherapy and higher costs in older
patients. Genomic testing in actual practice may “rule out” chemotherapy in younger women, and “rule in”
chemotherapy in older women.
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KEY FINDINGS: 
Genomic testing in patients with early-stage breast cancer is associated with decreased use of chemotherapy and lower costs 
in younger patients, and slightly increased use of chemotherapy and higher costs in older patients. Genomic testing in actual 
practice may “rule out” chemotherapy in younger women, and “rule in” chemotherapy in older women.
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Among women older than 75, however, RS testing 
increased chemotherapy use by almost 6 percentage points 
(from 8.7% to 14.4%) and increased medical spending by 
more than $3,000 (from $29,720 to $33,209). The authors 
found that the rate of RS testing decreased with age after 55.
THE QUESTION
The promise of personalized genomic testing is that it can 
reduce unnecessary care and costs by predicting which 
patients are most likely to benefit from a treatment. After 
surgery, women with early-stage breast cancer face the 
decision of whether to undergo expensive and potentially 
toxic chemotherapy to prevent recurrence, although 
most will not have a recurrence. The 21-gene recurrence 
score test (RS) was developed in 2004 to predict this 
risk, and its use in clinical medicine is increasing. In this 
study of actual treatment patterns, LDI Senior Fellows 
Andrew Epstein and Peter Groeneveld and colleagues 
investigate how genomic testing of women with early-
stage breast cancer affects subsequent chemotherapy 
use and medical spending in the year after diagnosis.
THE FINDINGS
The study found that RS testing influenced treatment 
decisions and medical expenses differently for younger 
and older patients. Among women younger than 55, 
RS testing was associated with a nearly 20 percentage 
point decrease in use of chemotherapy (from 60.8% 
to 41.5%) and $15,000 less in medical spending in the 
12 months after diagnosis (from $96,667 to $81,334). 
Incremental effect of RS receipt on probability of receiving chemotherapy and 
on total spending
The gold lines represent the difference in probability (0 to 1 scale) of chemotherapy 
use among RS recipients.  The blue lines represent the change in total health care 
costs (2010 $US) among RS recipients. The vertical lines indicate 95% CIs for the 
point estimates.
Source: Journal of Clinical Oncology, Dec 20, 2015
weighted regression models to find out whether and how RS 
testing influenced chemotherapy use and medical spending 
after diagnosis.  
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THE IMPLICATIONS
These findings have important policy implications for 
genomic testing. In real-world practice settings, RS testing 
was associated with substantial reductions in the use of 
chemotherapy and medical spending in younger women, 
implying that RS testing reduced unnecessary treatment—a 
critical goal of personalized medicine. Among elderly 
women, however, RS testing may provide impetus to use 
chemotherapy among patients with comorbidities.
Hence, RS testing may be commonly used among younger 
patients to “rule out” patients for chemotherapy, but, 
conversely, it may be used among older patients to “rule 
in” the use of chemotherapy patients who otherwise would 
not be candidates for chemotherapy due to their frailty or 
comorbid conditions. At a population level, the impact of RS 
testing is much greater for younger women. 
THE STUDY
The authors used the Pennsylvania Cancer Registry to 
assemble a cohort of 7,287 women who were diagnosed 
with early-stage breast cancer between 2007 and 2010 and 
had initial surgical treatment. Unlike most studies of cancer 
treatment, the authors studied patients who were covered 
both under Medicare (74%) and private insurance (26%). 
Compared to patients who did not receive RS testing, 
patients with RS testing were younger and more likely to 
have private insurance, have fewer comorbidities, and have 
stage I breast cancer. The registry data were combined with 
administrative claims data from traditional Medicare and 
Independence Blue Cross covering 12 months before and 
after diagnosis to identify patient comorbidities, treatments 
and expenditures. The authors used propensity score-
